The Vioxx recall is just the latest of several episodes this year that have prompted criticism of the FDA and Senate hearings. A panel talks about the drug approval process, post-marketing safety surveillance, and how the agency’s work affects Americans’ health and safety.

Guests

  • Dr. Jerry Avorn author of "Powerful Medicines," professor of medicine at Harvard Medical School, and chief of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital in Boston
  • Sen. Charles Grassley (R-Iowa), ranking member of the Senate Finance Committee
  • Marc Kaufman reporter on the national desk of "The Washington Post"
  • Alan Goldhammer, PhD associate vice president for regulatory affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA)
  • Dr. Sandra Kweder deputy director of the FDA's Office of New Drugs

Related Links

Topics + Tags

Comments

comments powered by Disqus
Most Recent Shows